An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder
Phase of Trial: Phase III
Latest Information Update: 28 Dec 2017
At a glance
- Drugs Dasotraline (Primary)
- Indications Binge-eating disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 27 Jun 2017 Planned number of patients changed from 225 to 500.
- 07 Mar 2017 Planned End Date changed from 1 Dec 2018 to 1 Nov 2019.
- 07 Mar 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Nov 2019.